Tunçbilek Işil, Ozdemir Ayşegül, Gültekin Serap, Oğur Törel, Erman Rabia, Yüce Cemal
Department of Radiology, Gazi University School of Medicine, Ankara, Turkey.
Diagn Interv Radiol. 2007 Dec;13(4):183-7.
To perform an audit of our routine mammographic practice and to compare our results to performance benchmarks.
We analyzed the outcomes of 7,506 consecutive examinations performed in 1 year. Screening and diagnostic cases were evaluated separately and mammographic assessments were based on the Breast Imaging Reporting and Data System (BI-RADS) classification.
In 6,858 (91%) screening and 648 (9%) diagnostic cases, outcomes varied substantially. The recall rate was 10.9%. Estimated sensitivity and specificity were similar (100% vs. 98% and 88% vs. 94%) in the screening and diagnostic groups. Positive predictive values (PPV1, PPV2, and PPV3) were higher in the diagnostic group compared to the screening group (64%, 65%, and 68% vs. 4.9%, 33%, and 39%, respectively). Cancer outcomes in the screening and diagnostic groups were, respectively, as follows: cancer detection rate, 6.1 per thousand vs. 86.4 per thousand; mean invasive cancer size, 15.7 mm vs. 24.5 mm; minimal cancers, 38% vs. 19%; stage 0-1 cancers, 50% vs. 21%; and lymph node negativity, 76% vs. 29%.
The measures of our screening outcomes were concordant with the literature and the performance benchmarks for screening mammography; however, in our diagnostic group, the reasons for the higher PPV, higher cancer detection rate, and the diagnosis of cancer in a more advanced stage compared to the performance benchmarks should be investigated with more detailed periodic audits.
对我们的常规乳腺钼靶检查实践进行审核,并将我们的结果与性能基准进行比较。
我们分析了1年内连续进行的7506例检查的结果。筛查和诊断病例分别进行评估,乳腺钼靶评估基于乳腺影像报告和数据系统(BI-RADS)分类。
在6858例(91%)筛查病例和648例(9%)诊断病例中,结果差异很大。召回率为10.9%。筛查组和诊断组的估计敏感性和特异性相似(分别为100%对98%和88%对94%)。与筛查组相比,诊断组的阳性预测值(PPV1、PPV2和PPV3)更高(分别为64%、65%和68%对4.9%、33%和39%)。筛查组和诊断组的癌症结果分别如下:癌症检出率,每千例中6.1例对86.4例;平均浸润性癌大小,15.7mm对24.5mm;微小癌,38%对19%;0-1期癌症,50%对21%;以及淋巴结阴性,76%对29%。
我们的筛查结果指标与文献以及乳腺钼靶筛查的性能基准一致;然而,在我们的诊断组中,与性能基准相比,PPV更高、癌症检出率更高以及癌症诊断处于更晚期的原因应通过更详细的定期审核进行调查。